DMRA
Neutral signalScored 2026-10-20 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Damora Therapeutics, Inc.
- Nom
- Damora Therapeutics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $1.3B
- Employés
- 7
- PDG
- Jennifer A. Jarrett
- Site web
- https://www.damoratx.com
- Marché
- COAGGERNGMABINCYIRONKROS
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company’s lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to ultimately address the full spectrum of mutCALR MPN patients. It also develops GB3226, a small molecule inhibitor of ENL-YEATS and FLT3 for the treatment of acute myeloid leukemia. Damora Therapeutics, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 12 500 titres (~252 875,00 $ US)
- Insiders
- Jarrett Jennifer
- Total bought
-
$252,875
Avg buy (VWAP, 90d window) $20.23 vs last close $21.26 (+5.1%)
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-09-25
- Liquidity
- Thin $10,183,725/day · 20d vol
- Last synced
-
2026-10-26 21:10:23
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-25 | Jarrett Jennifer | Buy · P | 12,500 | $20.23 | $252,875 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-10-20 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
DMRA presents a stark disconnect between a strong liquidity score (85) and near-total absence of commercial operations, with zero revenue and consistently negative returns suggesting a shell or dormant entity.
The first sentence of the analysis written for DMRA on 2026-10-20 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 12.98 · operating margin 0.0%
Suggested stop 20.54, nearest stored support minus 0.5 ATR(3.4% under the last close). Reward/risk to the next stored resistance is 6.43. Research, not advice. Not an order.
Recent news
- 2026-10-03 Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Shares Gap Down – Time to Sell? Damora Therapeutics, Inc. Common Stock (NASDAQ: DMRA - Get Free Report) gapped down before the market opened on Thursday. The stock had previously closed at $21.28, but opened at $20.51. Damora Therapeutics, Inc. Common Stock shares last traded at $20.77, with a volume of 20,170 shares trading hands. Analyst Ratings Changes DMRA has been the topic
- 2026-10-02 Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to five newly-hired, non-executive employees on October 1, 2026. The inducement grants were approved by Damora''s independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals'' acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).
- 2026-09-29 Damora CEO buys 12,500 shares in open market What happened Damora Therapeutics, Inc. (NASDAQ: DMRA) said Jennifer Jarrett bought 12,500 ordinary shares on 2026-09-25. Jarrett is the company''s director, president and CEO. The Form 4 says the shares were bought at a weighted average price of $20.23 each, for about $252,875. The filing was signed on 2026-09-28. The shares were bought on the
- 2026-09-28 Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) CEO Jennifer Jarrett Purchases 12,500 Shares of Company Stock Damora Therapeutics, Inc. Common Stock (NASDAQ: DMRA - Get Free Report) CEO Jennifer Jarrett bought 12,500 shares of the business''s stock in a transaction dated Friday, September 25th. The shares were acquired at an average cost of $20.23 per share, for a total transaction of $252,875.00. Following the purchase, the chief executive officer owned 512,500 shares
- 2026-09-03 Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to three newly-hired, non-executive employees on September 1, 2026.
- 2026-08-12 Damora Therapeutics: Competition Validates The Target While Its Portfolio Creates The Upside Damora Therapeutics is advancing a differentiated portfolio targeting mutant calreticulin (mutCALR) in ET and MF, with three escalating mechanism programs. DMRA''s lead candidate, DMR-001, offers up to 30x potency and 5x half-life over comparators, supporting convenient monthly subcutaneous dosing. CLARITY-101 trial design accelerates clinical evaluation, with proof-of-concept data expected mid-2027 and Phase 3 potentially starting mid-2028.
- 2026-08-05 Damora Therapeutics Initiates Phase 1/1b CLARITY-101 Clinical Trial of DMR-001 in Patients with Mutant Calreticulin-Driven Essential Thrombocythemia and Myelofibrosis -- DMR-001 is a highly potent, long-acting antibody therapy targeting Type 1 and non-Type 1 mutant calreticulin (mutCALR), designed for convenient once-monthly subcutaneous dosing -- -- In preclinical studies, DMR-001 demonstrated up to 30-fold greater potency and an approximately five-fold longer half-life than a reference anti-mutCALR antibody, supporting its best-in-class potential -- WALTHAM, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced the initiation of the global Phase 1/1b CLARITY-101 clinical trial of DMR-001, an investigational monoclonal antibody therapy designed to selectively target mutant calreticulin (mutCALR), in patients with mutCALR-driven essential thrombocythemia (ET) and myelofibrosis (MF), based on receipt of health authority approval.
- 2026-08-03 Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BOSTON, Aug. 03, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to six newly-hired, non-executive employees on August 1, 2026. The inducement grants were approved by Damora''s independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals'' acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 12.978 | 14.068 | 6.308 | 5.754 | 24.230 | |
| Quick Ratio | 12.978 | 14.068 | 6.308 | 5.754 | 24.230 | |
| Solvency Ratio | -10.414 | -7.989 | -6.363 | -5.346 | -10.279 | |
| Cash Ratio | 12.839 | 11.842 | 3.682 | 2.952 | 13.768 | |
| Price To Earnings Ratio | -0.150 | -0.251 | -0.499 | -0.474 | -1.479 | |
| Price To Earnings Growth Ratio | -0.000 | 0.005 | 0.012 | -0.026 | -0.030 | |
| Forward Price To Earnings Growth Ratio | -0.000 | 0.005 | 0.012 | -0.026 | -0.030 | |
| Price To Earnings Diluted Ratio | -0.150 | -0.251 | -0.499 | -0.474 | -1.479 | |
| Price To Earnings Diluted Growth Ratio | -0.000 | 0.005 | 0.012 | -0.026 | -0.030 | |
| Price To Book Ratio | 0.130 | 0.372 | 0.592 | 0.473 | 0.653 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -4.663 | -0.289 | -0.518 | -0.678 | -1.457 | |
| Price To Operating Cash Flow Ratio | -4.663 | -0.289 | -0.518 | -0.681 | -1.463 | |
| Debt To Assets Ratio | 0.000 | 0.084 | 0.007 | 0.011 | 0.007 | |
| Debt To Equity Ratio | 0.000 | 0.099 | 0.008 | 0.013 | 0.007 | |
| Debt To Capital Ratio | 0.000 | 0.090 | 0.008 | 0.013 | 0.007 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.086 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.084 | 1.184 | 1.182 | 1.185 | 1.043 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -0.335 | -15.558 | -6.331 | -3.865 | -11.511 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.000 | 1.000 | 1.005 | 1.004 | |
| Debt Service Coverage Ratio | 0.000 | -1,771.500 | -205.022 | -128.433 | -128.599 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | -1,551.917 | -201.699 | -90.193 | -131.098 | |
| Operating Cash Flow Coverage Ratio | -98.912 | -12.996 | -148.237 | -53.398 | -61.757 | |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | 0.000 | -219.041 | -234.565 | |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | 0.000 | -219.041 | -234.565 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | 1.078 | 0.347 | 0.056 | 0.045 | -0.289 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 12.978 | ▼-1.089 | ▲0.311 |
| Quick Ratio | 12.978 | ▼-1.089 | ▲0.311 |
| Solvency Ratio | -10.414 | ▼-2.425 | ▼-2.336 |
| Cash Ratio | 12.839 | ▲0.997 | ▲3.822 |
| Price To Earnings Ratio | -0.150 | ▲0.101 | ▲0.420 |
| Price To Earnings Growth Ratio | -0.000 | ▼-0.005 | ▲0.008 |
| Forward Price To Earnings Growth Ratio | -0.000 | ▼-0.005 | ▲0.008 |
| Price To Earnings Diluted Ratio | -0.150 | ▲0.101 | ▲0.420 |
| Price To Earnings Diluted Growth Ratio | -0.000 | ▼-0.005 | ▲0.008 |
| Price To Book Ratio | 0.131 | ▼-0.241 | ▼-0.314 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -4.663 | ▼-4.374 | ▼-3.142 |
| Price To Operating Cash Flow Ratio | -4.663 | ▼-4.374 | ▼-3.140 |
| Debt To Assets Ratio | 0.000 | ▼-0.083 | ▼-0.021 |
| Debt To Equity Ratio | 0.000 | ▼-0.099 | ▼-0.025 |
| Debt To Capital Ratio | 0.000 | ▼-0.090 | ▼-0.023 |
| Long Term Debt To Capital Ratio | 0.000 | ▼-0.086 | ▼-0.017 |
| Financial Leverage Ratio | 1.084 | ▼-0.100 | ▼-0.052 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -0.335 | ▲15.223 | ▲7.185 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 0.000 | ▼-0.002 |
| Debt Service Coverage Ratio | 0.000 | ▲1771.500 | ▲446.711 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | ▲1551.917 | ▲394.981 |
| Operating Cash Flow Coverage Ratio | -98.912 | ▼-85.916 | ▼-23.852 |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | ▲90.721 |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | ▲90.721 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | 1.078 | ▲0.731 | ▲0.831 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $31.4M | $5.4M | $19.1M | $29.2M | $76.5M | |
| Enterprise value | -$226.2M | -$7.4M | -$2.1M | -$2.8M | $14.8M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | 33.63x | 0.40x | 0.06x | 0.06x | -0.28x | |
| EV / Free cash flow | 33.63x | 0.40x | 0.06x | 0.06x | -0.28x | |
| EV / EBITDA | 1.08x | 0.35x | 0.06x | 0.04x | -0.29x | |
| Net debt / EBITDA | 1.23x | 0.60x | 0.56x | 0.52x | 1.20x | |
| Current ratio | 12.98x | 14.07x | 6.31x | 5.75x | 24.23x | |
| Income quality | 0.03x | 0.87x | 0.96x | 0.70x | 1.01x | |
| Graham net-net | $175 | $11 | $27 | $49 | $96 | |
| Tax burden | 100.0% | 100.2% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $240.4M | $15.6M | $30.9M | $52.8M | $105.6M | |
| Invested capital | $240.5M | $15.8M | $31.3M | $54.0M | $106.6M | |
| Return on assets | -80.5% | -125.1% | -100.3% | -84.2% | -42.3% | |
| Operating ROA | -151.9% | -61.0% | -65.4% | -62.6% | -35.6% | |
| Return on tangible assets | -80.5% | -125.1% | -100.3% | -84.2% | -42.3% | |
| Return on equity | -87.3% | -148.2% | -118.6% | -99.8% | -44.1% | |
| Return on invested capital | -87.7% | -106.0% | -111.9% | -97.8% | -44.2% | |
| Return on capital employed | -87.7% | -106.0% | -112.5% | -98.6% | -44.4% | |
| Earnings yield | -669.1% | -398.4% | -200.4% | -210.9% | -67.6% | |
| Free cash flow yield | -21.4% | -346.1% | -192.9% | -147.6% | -68.6% | |
| Capex / Op. cash flow | 0.0% | 0.0% | 0.0% | -0.5% | -0.4% | |
| Capex / Depreciation | 0.0% | 0.0% | 0.0% | 40.0% | 50.6% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 760d | 748d | 2495d | 1267d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | -760d | -748d | -2495d | -1267d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
No employee-count data synced.